Premium
Cancer nanotechnology research in the United States and China: cooperation to promote innovation
Author(s) -
Schneider Julie A.,
Grodzinski Piotr,
Liang XingJie
Publication year - 2011
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.149
Subject(s) - nanomedicine , china , dialog box , political science , nanotechnology , business , engineering ethics , engineering , medicine , computer science , materials science , world wide web , nanoparticle , law
The application of nanotechnology to cancer research is a promising area for US–China cooperation. Cancer is a major public health burden in both countries, and progress in cancer nanotechnology research is increasing in several fields, including imaging, biomarker detection, and targeted drug delivery. The United States and China are international leaders in nanotechnology research, and have both launched national programs to support nanotechnology efforts in the recent past. The accelerating trend of co‐authorship among US and Chinese nanotechnology researchers demonstrates that individual scientists already recognize the potential for cooperation, providing a strong platform for creating additional partnerships in pre‐competitive research areas. Mechanisms that could help to enhance US–China cancer nanotechnology partnerships include: developing new programs for bi‐directional training and exchange; convening workshops focused on specific scientific topics of high priority to both countries; and joint support of collaborative research projects by US and Chinese funders. In addition to the accelerating scientific progress, expanded cooperation will stimulate important dialog on regulatory, policy, and technical issues needed to lay the groundwork for US and Chinese scientists to move greater numbers of cancer nanotechnology applications into the clinic. WIREs Nanomed Nanobiotechnol 2011 3 441–448 DOI: 10.1002/wnan.149 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine